Synthetic Biology and the “Bioeconomy”: Feeding Fuel to the Fire of Landgrabs and
Biodiversity Loss
By Eric Hoffman and Jeff Conant,
Global Forest Coalition
| 02. 14. 2013
[For footnotes, see here]
The industrial revolution replaced wood for fossil fuels as the driver of the engine of progress, leaving living plants to take a back seat in energy production. Now, with the advent of a set of technologies known as synthetic biology, industry groups and the US Department of Energy are celebrating the advent of a new “bioeconomy” – an energy and materials economy in which products and processes previously derived from petroleum will be produced through the exploitation of biomass and biotechnology. By employing the rapidly expanding techniques of synthetic biology, the new industrialists want to turn microbes into “living chemical factories” engineered to produce substances they would not produce naturally, such as biofuels, bio-plastics, industrial chemicals and oils, and even medicines.
However, early indications show that such an approach likely harbors all of the ill-effects of the fossil fuel economy – simply swapping out black carbon for green – combined with the assault on biodiversity brought on by biotechnologies such as genetic engineering of crops. Humans have already caused a state-shift in the global ecosystem...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...